Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPN10200 phase I/II study in adult upper limb spasticity
2023-507202-14-00Phase 2Authorised
- Sponsor
- Ipsen
- Start
- Apr 2021
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial of corabotase in upper extremity spasticity (4 arms), sponsored by Ipsen. Primary endpoints: Treatment-emergent adverse events, Adverse events of special interest and 6 more. Planned start Apr 2021; status: authorised.
02
Drugs
corabotase
03
Conditions
upper extremity spasticity
Beyond the preview
Go deeper on 2023-507202-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507202-14-00.